topic

576 NL-201, a de novo IL-2 and IL-15 agonist, demonstrates enhanced in vivo antitumor activity in combination with multiple cancer immunotherapies
Carl Walkey, Ryan Swanson, Umut Ulge, Daniel Adriano Silva Manzano, Jonathan Drachman

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A346; DOI: 10.1136/jitc-2020-SITC2020.0576
600 In vitro anticancer and immunomodulatory activities of NBT-167, a dimer of resveratrol
Jeffrey Zhang, Everett Henry, L Harris Zhang, Wanying Zhang

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A358-A359; DOI: 10.1136/jitc-2020-SITC2020.0600
604 Intravenous CMP-001, a CpG-A Toll-like receptor 9 (TLR9) agonist delivered via a virus-like particle, causes tumor regression in syngeneic Hepa1–6 mouse models of hepatocellular carcinoma
Aaron Morris, Evan Walters, Bassel Akache, Michael McCluskie, Arthur Krieg

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A360-A361; DOI: 10.1136/jitc-2020-SITC2020.0604
605 Systemically administered HER2-targeted ISACs provoke a rapid, local response that engages the innate and adaptive arms of the immune system to eradicate tumors in preclinical models
Heidi LeBlanc, Cecelia Pearson, Justin Kenkel, LIsa Blum, Po Ho, Angela Luo, Richard Laura, Matthew Zhou, Joshua Gregorio, Andrew Luo, Shelley Ackerman, Brian Safina, David Dornan, Michael Alonso, Marcin Kowanetz

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A361-A362; DOI: 10.1136/jitc-2020-SITC2020.0605
58 Excluding treg epitopes and integrating CD8 and CD4 effector neoepitope content improves prognostic biomarker tool in bladder cancer
Guilhem Richard, Gary Steinberg, Tzintzuni Garcia, Matthew Ardito, William Martin, Gad Berdugo, Michael Princiotta, Arjun Balar, Anne de Groot, Randy Sweis

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A37; DOI: 10.1136/jitc-2020-SITC2020.0058
628 IL-2 augments immTAC-dependent T cell activation and tumour cell killing
Duncan Gascoyne, Kristina Petrovic, Koustubh Ranade, David Depoil

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A377; DOI: 10.1136/jitc-2020-SITC2020.0628
632 HPN601 is a protease-activated EpCAM-targeting T cell engager with an improved safety profile for the treatment of solid tumors
Jack Lin, Sony Rocha, Kathryn Kwant, Maria Dayao, Tessie Ng, Wade Aaron, Evan Callihan, Maria Gamez-Guerrero, Golzar Hemmati, Kevin Wright, Manasi Barath, Yinghua Xiao, Master Degree, Timothy Yu, Patrick Chew, Thomas Evans, Jessica O’Rear, Scott Gatto, Michael Cremin, Stephen Yu, Purbasa Patnaik, Avneel Hundal, Richard Austin, Bryan Lemon, Holger Wesche

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A379; DOI: 10.1136/jitc-2020-SITC2020.0632
637 Immune-related adverse events (irAEs) may indicate a favorable prognosis in metastatic renal cell carcinoma (mRCC) patients treated with immune checkpoint inhibitors (ICI)
Dylan Martini, Sean Evans, Subir Goyal, Yuan Liu, T Anders Olsen, Benjamin Magod, Jacqueline Brown, Lauren Yantorni, Greta Russler, Sarah Caulfield, Jamie Goldman, Bassel Nazha, Wayne Harris, Viraj Master, Omer Kucuk, Bradley Carthon, Mehmet Bilen

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A380-A381; DOI: 10.1136/jitc-2020-SITC2020.0637
634 Production and testing of a novel bispecific nanobody construct targeting NK cells and EGFR expressing malignancies
Elisa Toffoli, Abdolkarim Sheikhi, Roeland Lameris, Lisa King, Jurriaan Tuynman, Jan Spanholtz, Henk Verheul, Tanja de Gruijl, Hans Van der Vliet

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A380; DOI: 10.1136/jitc-2020-SITC2020.0634
67 B-cell receptor heavy chain repertoire profiling using an augmented transcriptome
Eric Levy, Pamela Milani, Gabor Bartha, Charles Abbott, Robert Power, Rena McClory, Robin Li, John West, John Lyle, Sean Boyle, Richard Chen

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A41; DOI: 10.1136/jitc-2020-SITC2020.0067

Main menu

topic

Pages

Log in using your username and password

Main menu

Log in using your username and password

You are here

topic

Pages